Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and welcome to the Personalis Fourth Quarter 2024 Earnings Conference Call.
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.46 per share a year ago.
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exciting Technology At Personalis, But Profitability Eludes Them
Personalis specializes in ultrasensitive cancer detection technology, with promising products like NeXT Personal and ImmunoID NeXT, but faces profitability challenges. The company has strong financials with a good cash position and no debt, but struggles with test reimbursement impacting gross margins. Partnerships with Tempus AI and Merck provide capital and credibility, but profitability is projected to be years away, possibly until 2029.
Personalis (PSNL) Upgraded to Buy: Here's Why
Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Personalis price target raised to $9 from $7 at Lake Street
Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. With cash to breakeven, a strong commercial partner, "robust" clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as "another transformative year" for Personalis, the analyst tells investors.
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.
Personalis: Resetting My Strategy Following The Q2 Beat
PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position.
Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?
Personalis (PSNL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis Second Quarter 2024 Earnings Conference Call.
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
